Indivior’s (INDV) Buy Rating Reiterated at Jefferies Group

Jefferies Group reiterated their buy rating on shares of Indivior (LON:INDV) in a research note published on Wednesday, January 17th. Jefferies Group currently has a GBX 500 ($6.91) price target on the specialty pharmaceutical company’s stock.

Several other brokerages have also issued reports on INDV. Morgan Stanley restated an equal weight rating and issued a GBX 410 ($5.66) price objective on shares of Indivior in a report on Friday, December 1st. Numis Securities reaffirmed a buy rating and issued a GBX 500 ($6.91) target price on shares of Indivior in a research report on Monday, October 30th. Citigroup raised Indivior to a buy rating and boosted their price objective for the stock from GBX 280 ($3.87) to GBX 490 ($6.77) in a research report on Wednesday, November 8th. Finally, Royal Bank of Canada reissued an outperform rating and set a GBX 500 ($6.91) price objective on shares of Indivior in a research report on Friday, December 1st. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of GBX 482.14 ($6.66).

Shares of Indivior (LON INDV) traded up GBX 7.50 ($0.10) during mid-day trading on Wednesday, reaching GBX 390.20 ($5.39). The company’s stock had a trading volume of 2,094,626 shares, compared to its average volume of 1,600,000. Indivior has a 12 month low of GBX 246.50 ($3.41) and a 12 month high of GBX 436.60 ($6.03). The stock has a market cap of $2,820.00 and a price-to-earnings ratio of 1,500.77.

WARNING: “Indivior’s (INDV) Buy Rating Reiterated at Jefferies Group” was first reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at

About Indivior

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with's FREE daily email newsletter.

Leave a Reply